Welcome to our dedicated page for Iqvia Hldgs news (Ticker: IQV), a resource for investors and traders seeking the latest updates and insights on Iqvia Hldgs stock.
IQVIA Holdings Inc. (IQV) delivers integrated healthcare insights through its unique combination of clinical research expertise and advanced data analytics. This news hub provides investors and industry professionals with timely updates on corporate developments shaping the life sciences sector.
Access official press releases and curated news coverage spanning clinical trial milestones, healthcare data partnerships, regulatory updates, and technology innovations. Our collection serves as a strategic resource for understanding IQVIA's role in optimizing drug development cycles and commercial decision-making.
Key content categories include earnings announcements, merger/acquisition activity, leadership changes, and analytical breakthroughs in real-world evidence applications. Bookmark this page for efficient tracking of IQVIA's progress in transforming clinical research through data-driven solutions.
IQVIA Holdings (NYSE:IQV) has scheduled its fourth-quarter and full-year 2024 financial results announcement for Thursday, February 6, 2025, before market opening. The management team will host a conference call and webcast at 9:00 a.m. Eastern Time on the same day.
The earnings release and financial information will be available on IQVIA's Investor Relations website. Interested parties must register in advance to participate in the conference call, after which they will receive confirmation details including dial-in information and unique access credentials. A webcast replay will be accessible approximately two hours after the event conclusion.
IQVIA (NYSE:IQV) announced a strategic collaboration with NVIDIA to advance AI applications in healthcare and life sciences. The partnership aims to accelerate IQVIA Healthcare-grade AI™, enabling automated workflows across therapeutic lifecycles while maintaining privacy, regulatory compliance, and patient safety standards.
The collaboration combines IQVIA's Connected Intelligence™ with NVIDIA's AI Foundry service to transform life science processes from R&D through commercialization. IQVIA will utilize NVIDIA's technology stack, including NIM microservices, NeMo, and DGX Cloud platform, with support from NVIDIA's research teams.
Initial solutions from this partnership are expected to reach the market within the calendar year. The collaboration will implement NVIDIA AI Blueprint for multi-modal data extraction, making previously inaccessible information available to AI models and agents.
Digital health continues to evolve with 337,000 apps currently available, alongside 360+ software-based digital therapies and 103 digital diagnostics commercially available. Disease-specific apps are expanding beyond mental health and chronic diseases, with 140 prescription digital therapeutics (DTx) approved for home use and 220+ therapies used in clinical settings.
Despite decreased venture funding, digital health solutions are growing in scope, focusing on specific diseases and integrating AI to personalize care. Germany leads in DTx regulation with 56 approved therapies, followed by the US (46) and UK (20). Notable developments include sensor-based digital biomarkers for patient monitoring, FDA-approved digital endpoints, and AI/ML-enabled diagnostic tools, with 801 AI/ML devices approved by FDA as of June 2024.
IQVIA Holdings (NYSE:IQV) has announced that Ron Bruehlman, executive vice president and chief financial officer, will present at the UBS Healthcare Conference in Rancho Palos Verdes, California. The presentation is scheduled for November 13, 2024, at 1:15 p.m. ET. Interested parties can access a live audio webcast of the presentation through the IQVIA Investor Relations website, with a replay available later the same day.
IQVIA reported Q3 2024 results with revenue of $3,896 million, up 4.3% year-over-year. Technology & Analytics Solutions revenue grew 8.6% to $1,554 million, while R&D Solutions revenue increased 1.9% to $2,162 million. The company achieved GAAP Net Income of $285 million and Adjusted EBITDA of $939 million.
R&D Solutions backlog reached $31.1 billion, up 8.0% year-over-year, with a book-to-bill ratio of 1.06x. Operating Cash Flow was $721 million, and Free Cash Flow was $571 million. The company updated its full-year 2024 guidance, projecting revenue between $15,350-15,400 million and Adjusted EBITDA between $3,675-3,700 million.
IQVIA Holdings Inc. (NYSE:IQV) has announced it will release its third-quarter 2024 financial results on Thursday, October 31, 2024, before the market opens. The company will host a conference call and webcast at 9:00 a.m. Eastern Time on the same day to discuss the results. Investors can access the earnings release and financial information on IQVIA's Investor Relations website.
To participate in the conference call, interested parties must register in advance through a provided link. Upon registration, participants will receive confirmation details for joining the call. The webcast can be accessed from the IQVIA Investor Relations website, and a replay will be available approximately two hours after the live event concludes.
IQVIA (NYSE:IQV) has introduced IQVIA AI Assistant, a generative AI technology designed to enhance how life science customers receive timely and powerful insights. This user-friendly, conversational text interface provides immediate analytic insights on topics such as brand and territory performance, competitive intelligence, and prescription drivers.
The AI Assistant is built on IQVIA Healthcare-grade AI™, which combines high-quality healthcare data with privacy safeguards and validated models. IQVIA is integrating this technology into various solutions, including Orchestrated Analytics, ChannelDynamics®Verbatim, Market Prognosis, and Clinical Data Analytics Solutions, enabling near real-time insights that previously required extensive expert analysis.
IQVIA (NYSE:IQV) has been awarded the 2024 Global Customer Value Leadership Award by Frost & Sullivan for excellence in AI quality and regulatory solutions for healthcare. The recognition is for IQVIA's Enterprise Quality Management System (eQMS), SmartSolve®, which simplifies quality and regulatory compliance processes. SmartSolve is an intelligence-driven platform that improves patient safety, enhances product quality, and maintains compliance.
The platform is powered by IQVIA Healthcare-grade AI™, designed to meet the precision, speed, and trust requirements of life sciences and healthcare. IQVIA's approach combines intelligence-driven simplification, integration, and automation to transform quality operations and drive efficiency for QA/RA professionals.
Signant Health, a leader in clinical trial evidence generation, has joined IQVIA's One Home for Sites™ initiative. This collaboration aims to simplify clinical research by providing a single sign-on platform for sites to access multiple eClinical technologies. Signant's SmartSignals® Unified Platform, which includes eCOA, EDC, RTSM, eConsent, and telemedicine, will be available through One Home for Sites.
Sanjiv Waghmare, Signant's chief product officer, expressed enthusiasm for the partnership, noting its alignment with Signant's strategy to provide unified access to their products. Melissa Easy, VP of Commercialization for IQVIA Technologies, welcomed Signant's contribution to building a next-generation clinical trial ecosystem that benefits all stakeholders, particularly patients.
IQVIA Holdings Inc. (NYSE:IQV) has announced that its CFO, Ron Bruehlman, will be speaking at the Morgan Stanley Annual Global Healthcare Conference on September 4, 2024 at 10:00 a.m. ET in New York. This event presents an opportunity for investors and analysts to gain insights into IQVIA's financial strategies and market positioning.
The presentation will be accessible via a live audio webcast on IQVIA's Investor Relations website. For those unable to attend or listen live, a replay of the webcast will be made available later the same day, ensuring wide access to the information shared during the conference.
This appearance at a major healthcare conference underscores IQVIA's commitment to transparency and engagement with the investment community, potentially impacting investor sentiment and the company's stock performance.
